article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018. The most telling data on a disconnect between drug prices and research costs has received almost no public attention.

Pharma 255
article thumbnail

Company profile: NeoImmuneTech

pharmaphorum

At NeoImmuneTech, a Biotech company founded in Maryland, US, in 2014, the answer to this question looks straightforward: “We believe in incremental progress”, says Dr Se Hwan Yang, president and chief executive officer of the company. NT-I7 exhibits reliable Pharmacokinetic (PK) and safety profiles, making it an ideal combination partner.

Safety 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Norstella, Citeline merge to create $5bn pharma tech firm

pharmaphorum

As a result, it can “quickly answer key questions related to the patient journey, payer reimbursement, and the safety and efficacy of therapeutics,” said Norstella.

Pharma 101
article thumbnail

FDA accepts BLA for Pfizer’s haemophilia B gene therapy

Pharma Leaders

Based on the safety and efficacy findings from the Phase III BENEGENE-2 study, the company made these filings. Fidanacogene elaparvovec also demonstrated to be well-tolerated, with a safety profile in line with Phase I/II data. Pfizer obtained the licence for gene therapy from Spark Therapeutics in December 2014.

article thumbnail

Pfizer’s haemophilia B gene therapy meets phase 3 primary endpoint

pharmaphorum

Key secondary endpoints demonstrated a 78% reduction in treated ABR and a 92% reduction in annualised infusion rate, and SPK-9001 was generally well-tolerated, its safety profile consistent with phase 1 and phase 2 results. This resulted in a 71% reduction in ABR after a single dose of 5e11 vg/kg of fidanacogene elaparvovec.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.”

article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Despite the tidal wave of renewed interest in psychedelic therapies, there is still much to be learned about them, including their precise mechanisms of action, their long- and short-term safety profiles, the durability of their effect, and their adverse effects—which can be severe. Authorisation under exceptional circumstances.